Alex Goldberg

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/18/2014 -- -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR).

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) a biopharmaceutical company that engages in the development of therapeutic products in the United States is currently up (+2.70%) on 2,010,724 shares traded. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is currently up (+424.08%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) a biopharmaceutical company that provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications is currently up (+8.56%) on 3,077,275 shares traded after Questcor Announced to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014. Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) is currently up (+185.26%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com